Retinal penetration of calpain inhibitors in rats after oral administration

Journal of Ocular Pharmacology and Therapeutics

Volumn 22, Issue 6, 2006, Pages 417-424

  Shirasaki, Yoshihisa ^a   Yamaguchi, Masazumi ^a   Miyashita, Hiroyuki ^b  

^a SENJU PHARMACEUTICAL CO LTD   (Japan)

^b KUMAMOTO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CALPASTATIN; SJA 6017; SNJ 1715; SNJ 1945; SNJ 2008; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG PENETRATION; DRUG STRUCTURE; DRUG TISSUE LEVEL; ENZYME INHIBITION; MALE; NERVE CELL NECROSIS; NERVE DEGENERATION; NONHUMAN; PROTEIN DEGRADATION; RAT; RETINA ISCHEMIA;

ADMINISTRATION, ORAL; ANIMALS; CALPAIN; CHROMATOGRAPHY, LIQUID; ENZYME INHIBITORS; HALF-LIFE; INJECTIONS, INTRAVENOUS; MALE; MOLECULAR STRUCTURE; RATS; RATS, SPRAGUE-DAWLEY; RETINA; STRUCTURE-ACTIVITY RELATIONSHIP; TANDEM MASS SPECTROMETRY;

EID: 33846206126     PISSN: 10807683     EISSN: None     Source Type: Journal    
DOI: 10.1089/jop.2006.22.417     Document Type: Article

References (31)

1. Branca, D. Calpain-related diseases. Biochem. Biophys. Res. Commun. 322:1098-1104, 2004.
2. Ono, Y., Sorimachi, H., and Suzuki, K. In Wang, K.K.W., and Yuen, P.-W., eds. Calpain: Pharmacology and Toxicology of Calcium-Dependent Protease, Philadelphia, PA: Taylor & Francis, 1999; 1-3.
3. Huang, Y., and Wang, K.K. The calpain family and human disease. Trends Mol. Med. 7:355-362, 2001.
4. Wang, K.K.W., and Yuen, P.-W. Calpain inhibition: An overview of its therapeutic potential. Trends Pharmacol. Sci. 15:412-419, 1994.
5. Stracher, A. Calpain inhibitors as therapeutic agents in nerve and muscle degeneration. Ann. N. Y. Acad. Sci. 884:52-59, 1999.
6. Yuen, P.-W., and Wang, K.K.W. Therapeutic potential of calpain inhibitors in neurodegenerative disorders. Exp. Opin. Invest. Drugs 5:1291-1304, 1996.
7. Zatz, M., and Starling, A. Calpains and disease. N. Engl. J. Med. 352:2413-2423, 2005.
8. Sakamoto, Y., Nakajima, T., Fukiage, C., et al. Involvement of calpain isoforms in ischemia-reperfusion injury in rat retina. Curr. Eye Res. 21:571-580, 2000.
9. Oka, T., Tamada, Y., Nakajima, M., et al. Presence of calpain-induced proteolysis in retinal degeneration and dysfunction in a rat model of acute ocular hypertension. J. Neurosci. Res. 83:1342-1351, 2006.
10. Sharma, A.K., and Rohrer, B. Calcium-induced calpain mediates apoptosis via caspase-3 in a mouse photoreceptor cell line. J. Biol. Chem. 279:35564-35572, 2004.
11. Paquet-Durand, F., Azadi, S., Hauck, S.M., et al. Calpain is activated degenerating photoreceptors in the rdl mouse. J. Neurochem. 96:802-814, 2006.
12. Donkor, I.O. A survey of calpain inhibitors. Curr. Med. Chem. 7:1171-1188, 2000.
13. Wells G.J., and Bihovsky, R. Calpain inhibitors as potential treatment for stroke and other neurodegenerative disease: Recent trends and developments. Exp. Opin. Ther. Patents 8:1707-1727, 1998.
14. Lee, K.S., Franks, S., Vanderklish, P., et al. Inhibition of proteolysis protects hippocampal neurons from ischemia. Proc. Natl. Acad. Sci. USA 57:7233-7237, 1991.
15. Rami, A., and Krieglstein, J. Protective effects of calpain inhibitors against neuronal damage caused by cytotoxic hypoxia in vitro and ischemia in vivo. Brain Res. 609:67-70, 1993.
16. Hong, S.-C., Goto, Y., Lanzino, G., et al. Neuroprotection with a calpain inhibitor in a model of focal cerebral ischemia. Stroke 25:663-669, 1994.
17. Markgraf, C.G., Velayo, N.L., Johnson, M.P., et al. Six-hour window of opportunity for calpain inhibition in focal cerebral ischemia in rats. Stroke 29:152-158, 1998.
18. Bartus, R.T., Hayward, N.J., Elliott, P.J., et al. Calpain inhibitor AK-295 protects neurons from focal brain damage. Stroke 25:2265-2270, 1994.
19. Neuhof, W., Götte, O., Trumbeckaite, S., et al. A novel water-soluble and cell-permeable calpain inhibitor protects myocardial and mitochondrial function in postischemic reperfusion. Biol. Chem. 384:1597-1603, 2003.
20. Raghava, S., Hammond, M., and Kompella, U.B. Periocular routes for retinal drug delivery. Exp. Opin. Drug Deliv. 1:99-114, 2004.
21. Fukiage, C., Azuma, M., Nakamura, Y., et al. SJA6017, A newly synthesized peptide aldehyde inhibitor of calpain: Amelioration of cataract in cultured rat lenses. Biochim. Biophys. Acta. 1361:304-312, 1997.
22. Inoue, J., Nakamura, M., Cui, Y., et al. Structure-activity relationship study and drug profile of N-(4-fluorophenylsulfonyl)-L-valyl-L-leucinal (SJA6017) as a potent calpain inhibitor. J. Med. Chem. 46:868-871, 2003.
23. Shirasaki, Y., Nakamura, M., Yamaguchi, M., et al. Exploration of orally available calpain inhibitors 2: Peptidyl hemiacetal derivatives. J. Med. Chem. 49:3926-3932, 2006.
24. Nakamura, M., Yamaguchi, M., Sakai, O., et al. Exploration of cornea permeable calpain inhibitors as anticataract agents. Bioorg. Med. Chem. 11:1371-1379, 2003.
25. Shirasaki, Y., Miyashita, H., Yamaguchi, M., et al. Exploration of orally available calpain inhibitors: Peptidyl α-ketoamides containing an amphiphile at P3 site. Bioorg. Med. Chem. 13:4473-4484, 2005.
26. Shirasaki, Y., Miyashita, H., and Yamaguchi, M. Exploration of orally available calpain inhibitors 3.: Dipeptidyl α-ketoamide derivatives containing pyridine moiety. Bioorg. Med. Chem. 14:5691-5698, 2006.
27. Hughes, P.M., Olejnik, O., Chang-Lin, J.E., et al. Topical and systemic drug delivery to the posterior segments. Adv. Drug Deliv. Rev. 57:2010-2032, 2005.
28. Steuer, H., Jaworski, A., Elger, B., et al. Functional characterization and comparison of the outer blood-retina barrier and the blood-brain barrier. Invest. Ophthalmol. Vis. Sci. 46:1047-1053, 2005.
29. Meyer, S.L., Bozyczko-Coyne, D., Mallya, S.K., et al. Biologically active monomeric and heterodimeric recombinant human calpain 1 produced using the baculovirus expression system. Biochem. J. 314:511-519, 1996.
30. Alker, D., Campbell, S.F., and Cross, P.E. Long-acting dihydropyridine calcium antagonists. 6. Structure-activity relationships around 4-(2,3-dichlorophenyl)-3-(ethoxycarbonyl)-2-[(2-hydroxyethoxy)methyl] -5-(methoxycarbonyl)-6-methyl-1,4-dihydropyridine. J. Med. Chem. 34:19-24, 1991.
31. Shirasaki, Y., Miyashita, H., Nakamura, M., et al. PCT Int. Appl. WO2005056519, 2005.